利民股份(002734.SZ):提請股東大會授權董事會辦理以簡易程序向特定對象發行股票
格隆匯4月17日丨利民股份(002734.SZ)公佈,公司於2025年4月17日召開第六屆董事會第四次會議和第六屆監事會第四次會議,審議通過了《關於提請股東大會授權董事會辦理以簡易程序向特定對象發行股票的議案》。根據中國證券監督管理委員會《上市公司證券發行註冊管理辦法》等相關規定,公司董事會擬提請股東大會授權董事會以簡易程序向特定對象發行股票,募集資金總額不超過人民幣3億元且不超過最近一年末淨資產的20%,授權期限爲自公司2024年度股東大會審議通過之日起至公司2025年度股東大會召開之日止。上述事項尚需提交股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.